Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections

Wapnir, Irene; Rijn, Matt van de; Nowels, Kent W.; Amenta, Peter S.; Walton, Kelly L.; Montgomery, Kelli; Greco, Ralph S.; Dohán, Orsolya; Carrasco, Nancy

doi:10.1210/jc.2002-021544

Cited by 255 publications

(311 citation statements)

References 38 publications

Supporting

Mentioning

264

Contrasting

Unclassified

Order By: Relevance

“…Native NIS expression in ovarian tumors has been detected by immunohistochemistry, but was reported to be weak and confined to the cytoplasm, where it would not be functional. 27 Although NIS gene transfer into ovarian cells in vitro has been reported previously, 15,28 this is the first study to report NIS-mediated 131 I therapy of ovarian tumors in an animal model. The ability of the virus to enter the cells is a major ratelimiting factor for the efficacy of gene therapy.…”

Section: Discussionmentioning

confidence: 94%

Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice

et al. 2005

View full text Add to dashboard Cite

“…Thyroid hyperoxidase (TPO) and lactoperoxidase are immunologically similar enzymes that have been identified in both thyroid and breast tissue (8,9). Sodium-iodide symporter (NIS) (10) is an intrinsic plasma membrane glucoprotein of thyroid follicular cells that is also expressed physiologically in lactating breast tissue (11) as well as in BC in some cases (12,13). Despite this pre-clinical evidence, there is a lack of robust clinical evidence on the association between BC and thyroid function abnormalities.…”

Section: Introductionmentioning

confidence: 99%

Is there an association between thyroid function abnormalities and breast cancer?

Angelousi

Diamanti-Kandarakis

Zapanti

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the association between thyroid function abnormalities and breast cancer and, in particular, the prognostic markers of breast cancer.. Subjects and methods: Baseline levels of thyrotropin, free triiodothyronine, free thyroxine and thyroid autoantibodies were measured in 97 women with primary breast cancer, 27 women with benign breast disease, and 4 women with atypical ductal hyperplasia. Their baseline levels were compared with those in 48 healthy women with a normal mammography in the last 2 years. Results: There were no significant associations between history of thyroid disease and breast cancer (p = 0.33). The mean baseline levels of triiodothyronine and thyrotropin did not differ significantly between the compared groups. The mean baseline levels of free thyroxine were found to be significantly higher in the breast cancer group, even after adjusting for thyroid replacement therapy. The presence of thyroid antibodies did not differ significantly between the compared groups. In a subgroup analysis, breast cancer cases with thyroid disease and particularly hypothyroidism had a significantly lower incidence of lymph node metastases compared with breast cancer cases without thyroid disease. Conclusions: Our data confirmed the proliferative effect of thyroid hormones on breast cells, which had previously been shown in vitro. Additionally, thyroid disease and particularly hypothyroid function appeared to be associated with a lower incidence of lymph node metastases. Further studies to determine the prognostic role of thyroid hormones in breast cancer are warranted. Arch Endocrinol Metab. 2017;61(1):54-61

show abstract

“…This can be correlated with data in the human PTC. It could be due to an increased intracellular NIS misexpression (Saito et al, 1998;Wapnir et al, 2003;Riesco-Eizaguirre and Santisteban, 2006), to conformational changes (Gérard et al, 2003) or to the non maturation of hNIS (Trouttet-Masson et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice

et al. 2008

View full text Add to dashboard Cite

Human rearranged RET/PTC3 (papillary thyroid carcinoma) proto-oncogene and high-risk human papillomavirus (HPV) type 16 E7 oncogene induces in the mouse a neoplastic transformation of thyroid follicular cells. We present a detailed immuno-histological study (170 mouse thyroids: RET/PTC3, E7, wild type, 2-to 10-month-old) with cell cycle proliferation and signalling pathway indicators. The characteristics of both models are different. There is an 'oncogene dependent' cellular signature, maintained at all studied ages in the E7 model, less in the RET/PTC3 model. During tumour development a large heterogeneity occurred in the Tg-RET/PTC3 model within a same tumour or within a same thyroid lobe. The Tg-E7 model was less heterogeneous, with a dominant goitrous pattern. The solid tumour already described in the RET/PTC3 models associated with cribriform patterns, suggested 'PTC spindle cell changes' as in humans PTC rather than the equivalent of the solid human PTC. Proliferation and apoptosis in the two thyroid models are related to the causal oncogene rather than reflect a general tumorigenic process. The thyroids of RET/PTC3 mice appeared as a partial and transient model of human PTCs, whereas the Tg-E7 mice do not belong to the usual PTC type.

show abstract

Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections

Cited by 255 publications

References 38 publications

Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice

Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice

Is there an association between thyroid function abnormalities and breast cancer?

Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice

Contact Info

Product

Resources

About